US launch of new LiDCOunity monitor
OREANDA-NEWS. LiDCO (AIM: LID), the hemodynamic monitoring company, announces it will be launching its new LiDCOunity monitor at the 2016 Annual Congress of Enhanced Recovery and Perioperative Medicine. The conference will be held in Washington DC from 20 April- 22 April 2016.
Interest in Enhanced Recovery programmes in the US has been growing since the late 2000's. The Duke University Medical Centre Enhanced Recovery Programme started in 2010, and since then many centres around the US have started similar programmes. The Company will use the conference to showcase the US launch of the LiDCOunity product which was recently granted approval by the FDA. The LiDCOunity combines the full suite of LiDCO technology allowing the patient to be monitored across the entire clinical pathway on a single monitor.
Matt Sassone, CEO of LiDCO, commented: "Given our increasing presence in the US, having been awarded a five year purchasing agreement by MedAssets, launching our new product in the US has additional importance. With the growing clinical adoption of Enhance Recovery programmes in the US it is important for us to attend this congress. We can meet like-minded professionals who are looking for new technologies to improve operating procedures and patient outcomes."
About LiDCO Group Plc (www.lidco.com)
LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.
Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.
LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.
LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).
LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:
· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug
· quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time
The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.
LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.
*BISTM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.
**CNAPTM is a trademark of CNSystems Medizintechnik AG.
LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network:
LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.
LiDCO's headquarters are in London and its shares are traded on AIM.